Arcus biosciences reports third quarter 2021 financial results and provides an update on our anti-tigit domvanalimab

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended september 30, 2021 and provided an update on the arc-7 study of domvanalimab. gilead sciences has initiated its opt-in review process to potentially obtain rights to the arcus anti-tigit program. if the option is exerci
RCUS Ratings Summary
RCUS Quant Ranking